CN107011406A - Compound with anti-tumor effect and preparation method and application thereof - Google Patents
Compound with anti-tumor effect and preparation method and application thereof Download PDFInfo
- Publication number
- CN107011406A CN107011406A CN201610059173.XA CN201610059173A CN107011406A CN 107011406 A CN107011406 A CN 107011406A CN 201610059173 A CN201610059173 A CN 201610059173A CN 107011406 A CN107011406 A CN 107011406A
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- pharmaceutically acceptable
- preparation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000000259 anti-tumor effect Effects 0.000 title description 9
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 6
- 201000005202 lung cancer Diseases 0.000 claims abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims description 12
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 239000003005 anticarcinogenic agent Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical class C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 150000001350 alkyl halides Chemical class 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 208000019065 cervical carcinoma Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229940020967 gemzar Drugs 0.000 claims description 2
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 claims description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 36
- 239000003814 drug Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 12
- 210000004185 liver Anatomy 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 4
- 201000010881 cervical cancer Diseases 0.000 abstract description 4
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 3
- 229960004316 cisplatin Drugs 0.000 abstract description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000463 material Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- -1 chloro ligustrazine Chemical compound 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 230000000118 anti-neoplastic effect Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000013563 matrix tablet Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical group C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- YRXIMPFOTQVOHG-UHFFFAOYSA-N 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound OC(=O)CN(C)C(=O)OC(C)(C)C YRXIMPFOTQVOHG-UHFFFAOYSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- DOTMOQHOJINYBL-UHFFFAOYSA-N molecular nitrogen;molecular oxygen Chemical compound N#N.O=O DOTMOQHOJINYBL-UHFFFAOYSA-N 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a compound with the following structure, a preparation method thereof and application thereof in preparing antitumor drugs. The compound of the invention has the activity of obviously inhibiting the growth of tumor cell lines (HepG-2, HT-29, Hela, BGC-823 and A549), but has less toxicity to human liver normal cell (L02) lines. Wherein, the antiproliferative activity of the compound LQC-C on a human colon cancer cell line HT-29, a human cervical cancer cell line Hela and a human lung cancer cell line A549 is superior to that of a positive drug cisplatin; but the cytotoxicity of the normal human liver cells L02 is obviously lower than that of the positive drug cisplatin.
Description
Technical field
The present invention relates to a kind of compound and its preparation method and application, and in particular to one kind has anti-swollen
Compound of knurl functionality and its preparation method and application.
Background technology
Often there is the tragedy of " cancer dead person dies ", especially liver cancer, knot in the treatment of cancer on Present clinical
The current not yet specific medicament of the pernicious canceration of the multiclass such as intestinal cancer, it is that current chemotherapy is cancer to trace it to its cause
One of major way, front-line chemotherapeutic agents are often caused while cancer cell is killed to normal body
Serious toxic side effect, for example:Renal toxicity, hepatotoxicity wind agitation, neurotoxicity etc..It is high for obtaining
The strong cancer therapy drug of effect, low toxicity, selectivity is the target that pharmacy worker seek assiduously, gratifying
It is that domestic and international current research finds that cell toxicant selectively strong compound has good druggability, accords with
Development trend (the Cancer Cell, 2015,28,240-252 being fated for accurate medical science;Int.J.Mol.
Sci.2015,16(7),16401-16413)。
The present invention is with betulic acid (BA) and crude drug with antitumor, anti-liver disease biological activity
Thing ligustrazine (TMP) is initiation material, carries out chemical split synthesis the compounds of this invention.To this
The activity rating of class compound deploys mainly around in terms of antitumor (especially liver cancer, intestinal cancer etc.),
Test respectively analog to 5 kinds of cancer cell systems (HepG-2, HT-29, Hela, BGC-823,
A549) and non-cancerous cells system (people normal cell lines of human liver L02) cytotoxic activity.
The content of the invention
First purpose of the present invention is to provide compound with the structure of formula 1 and preparation method thereof.
Second object of the present invention is application of the compound of offer formula 1 in antineoplastic is prepared.
Third object of the present invention is to provide a kind of pharmaceutical composition with antitumor action.
The purpose of the present invention is achieved by the following technical solution:
Compound or its pharmaceutically acceptable salt with the structure of formula 1,
Further, the compound can add formulation art customary adjuvant be made tablet, capsule,
The regular dosage forms such as granule, powder, oral liquid, injection.
The preparation method of compound of the present invention comprises the following steps:
Step 1, betulic acid is dissolved in organic solvent, with 2- chloromethyls -3,5,6- trimethyls
Pyrazine generates midbody compound ligustrazine-betulic acid ester (midbody compound in the basic conditions
TBA);
Step 2, midbody compound TBA reacts life in the presence of catalyst with methyl amimoacetic acid
Into compound L QC-C.
Further, above-mentioned reaction is carried out at -20 DEG C to 250 DEG C;The organic solvent be containing
The ether of 1-20 carbon atom, alcohol, alkane, aromatic hydrocarbon, ketone, alkyl halide, acid amides, nitrile, ester or
The mixture of their various ratios of person;Alkali used is triethylamine or potassium carbonate;The catalyst is 1-
Hydroxybenzotriazole (HOBT), 1- ethyls -3- (3- dimethylamine propyls) carbodiimide hydrochloride
(EDCI), 1,3- dicyclohexylcarbodiimides (DCC) or DMAP (DMAP).
Further, in above-mentioned preparation method, the mol ratio of raw material and chloro ligustrazine is 1:0.1~1:10;
The mol ratio of raw material and alkali is 1:0.1~1:10;The mol ratio of intermediate and methyl amimoacetic acid is 1:0.1~1:10;
The mol ratio of intermediate and catalyst is 1:0.1~1:10.
Reaction scheme of the present invention is:
Reaction condition and reagent:(a) AcOH, 30%H2O2, reflux, 90 DEG C, 6h;(b)Ac2O,
reflux,105℃,2h;(c)THF:MeOH:H2O=3:1:1,NaOH,1h;(d),THF,Tscl,
TEA,DMAP,12h.;(e)DMF,dry K2CO3,60℃,12h.(f)BOC-Sarcosine,
EDCI,DMAP,DCM,25℃,12h;(g)HCl(g)in EA,0℃,1h.
The present invention also provides the compound of formula 1 or its pharmaceutically acceptable salt is preparing antineoplastic
In application.
Further, the tumour is liver cancer, lung cancer, colon cancer, cervical carcinoma and gastric carcinoma cell lines.
The present invention also provides a kind of pharmaceutical composition, and said composition includes what is existed with therapeutically effective amount
The mixing of the compound of formula 1 or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient
Thing.
Further, the composition is also comprising at least one conventional anti-cancer drugs.
Further, the anticarcinogen be selected from endoxan, 5 FU 5 fluorouracil, taxol, adriamycin,
Etoposide, Irinotecan, oxaliplatin, cis-platinum or gemzar.
The present invention also provide treating cancer method, including give patient administration effective dose formula 1 change
Compound or its pharmaceutically acceptable salt.
To enable above-mentioned formulation to realize, pharmaceutically acceptable tax need to be added when preparing these formulations
Shape agent, such as filler, disintegrant, lubricant, suspending agent, adhesive, sweetener, flavoring
Agent, preservative etc., filler includes:Starch, pregelatinized starch, lactose, mannitol, crust
Element, microcrystalline cellulose, sucrose etc., disintegrant includes:Starch, pregelatinized starch, microcrystalline cellulose
Element, sodium carboxymethyl starch, PVPP, low-substituted hydroxypropyl cellulose, crosslinking carboxylic
Sodium carboxymethylcellulose pyce etc., lubricant includes:Magnesium stearate, lauryl sodium sulfate, talcum powder,
Silica etc., suspending agent includes:Polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar,
Hydroxypropyl methyl cellulose etc., adhesive includes, starch slurry, polyvinylpyrrolidone, hydroxypropyl
Methylcellulose etc., sweetener includes:Saccharin sodium, aspartame, sucrose, honey element, radix glycyrrhizae
Hypo acid etc., flavouring includes:Sweetener and various essence, preservative include:Parabens, benzene
Formic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the fixed, eucalyptus oil of acetic acid chloroethene etc..
It is of the present invention it is " pharmaceutically acceptable " expression compound or composition must in chemistry and/
Or it is compatible with the other compositions included in preparation in toxicology.
" therapeutically effective amount " represents that the compounds of this invention treats or prevents specified disease or symptom;
Weaken, improve or eliminate one or more symptoms of specified disease;Or prevention or delay specified disease
Or the amount of the breaking-out of symptom.
The compounds of this invention have substantially suppress tumor cell line (HepG-2, HT-29, Hela,
BGC-823, A549) growth activity but be that toxicity is smaller to people's normal cell lines of human liver (L02).Its
In, compound L QC-C to human colon cancer cell line HT-29, Human cervical cancer cell lines Hela with
And human lung cancer cell line A549 antiproliferative activities are better than positive drug cis-platinum;But to people's normal cell lines of human liver
L02 cytotoxicity is significantly lower than positive drug cis-platinum.
Experimental example 1MTT methods observe increasings of the compounds of this invention LQC-C to cancer cell and non-cancerous cells system
Grow influence
1. instrument and material
The type CO2 incubators of Thermo 3111;HFsafe Biohazard Safety Equipments;Multiskan GO enzymes
Mark instrument;Found board LD5-2B type table-type low-speed centrifuges in capital;Olympus IX71 are inverted fluorescence microscopy
Mirror modified form RPMI-1640 culture mediums, hyclone, 0.25% trypsin solution, tetrazolium bromide,
Phosphate buffer (the silent winged generation that biochemistry product Beijing Co., Ltd of match);Amresco diformazans
Base sulfoxide (DMSO);
Bel7402 HepG-2;Human colon cancer cell line HT-29;Human cervical cancer cell lines
Hela;Human gastric cancer cell line BGC-823;Human lung cancer cell line A549;People's normal cell lines of human liver L02;
Experimental agents:The compounds of this invention LQC-C (is prepared) by embodiment 1-4;Bulk drug river
Rhizome of chuanxiong piperazine (TMP), betulic acid (BA);Positive drug cisplatin for injection (DPP) (301001CF;
Qilu Pharmaceutical Co., Ltd.).
2. method
The culture of 2.1 different cell lines
HepG2, HT-29, Hela, BGC-823, A549 and L02 cell culture are containing 10%
In the 1640 culture medium of hyclone, 37 DEG C, 5% CO are positioned over2Incubated in incubator.Carefully
Born of the same parents grow in adhered state, observe upgrowth situation under inverted microscope, treat that cell quantity is appropriate
When Secondary Culture.
Thin and normal cell the inhibited proliferation of 2.2 pairs of tumours
Take the logarithm growth period HepG2, HT-29, Hela, BGC-823, A549 and L02 it is thin
Born of the same parents, are inoculated in 96 well culture plates with the quantity in 3 × 103/ holes, containing 5%CO2Humidifying culture
37 DEG C of culture 24h in case;100 μ L testing compounds are separately added into per hole, make ultimate density point
Not Wei 40.0,20.0,10.0,5.0,2.5,1.25 μM.Cell controls group and blank control are set
Group, medicine group repeats 4 holes per concentration, and cell controls group and blank control group repeat 3 holes.Culture
Continue to cultivate after 72h in case, add 20 μ L MTT to be incubated 4h, supernatant discarding per hole, then Jia 100
μ L DMSO, vibrate 10min, and ELIASA 490nm wavelength measures absorbance, records result,
And calculate the IC50 values of compound, cell inhibitory rate (%)=[1- (A administration-A blank)/(A is just
Normal-A blank)] × 100%.
3. result
3.1 the compounds of this invention LQC-C to 5 kinds of tumor cell lines (HepG2, HT-29, Hela,
BGC-823, A549) and people's normal cell lines of human liver L02 IC50Value is as shown in table 1.
As can be seen from Table 1, compound L QC-C shows preferable suppression to various cancer cells
Proliferative activity o f tumor, and its antitumor activity is better than raw material;Wherein, compound L QC-C
To human colon cancer cell line HT-29 and Human cervical cancer cell lines Hela and human lung cancer cell line A549
Antiproliferative activity is better than positive drug cis-platinum;But the cytotoxicity to people's normal cell lines of human liver L02 is substantially low
In positive drug cis-platinum.
IC50 values of the table 1LQC-C to different tumor cell lines and normal cell
4. conclusion
The compounds of this invention show suppress tumor cell line (HepG2, HT-29, Hela,
BGC-823, A549) propagation activity.
Embodiment
The preparation of the compound 2- chloromethyl -3,5,6- trimethylpyrazines (compound 5) of embodiment 1
Take ligustrazine 21.76g (160mmol) (compound 1) to be dissolved in 50ml glacial acetic acids, add
The hydrogen peroxide of 18ml (160mmol) 30% reacts 4h in 90 DEG C, supplements afterwards
The hydrogen peroxide of 18ml (160mmol) 30% continues to react 2h, and TLC is monitored to reaction completely, is cooled to
Room temperature, pH to 10 is adjusted with 50% sodium hydroxide, and dichloromethane is extracted, anhydrous sodium sulfate drying,
Filtering, recycling design obtains white ligustrazine list nitrogen oxygen (compound 2).Add in compound 2
Enter 15.1ml (160mmol) acetic anhydride, be heated to reflux 2.5h in 105 DEG C, TLC is monitored to having reacted
Quan Hou, removes excessive aceticanhydride under reduced pressure, obtains black slurry ligustrazine acetylate (compound 3).
This secondary black slurry thing is placed in 100ml (THF:MeOH:H2O=3:1:1) solution, is added portionwise
19.2g (480mmol) sodium hydroxide, stirring reaction 2h, dichloromethane extraction, anhydrous sodium sulfate is done
Dry, filtering is removed under reduced pressure solvent, obtains hydroxyl ligustrazine crude product, recrystallized, obtained with n-hexane
18.5g yellow needles (compound 4).This yellow crystal is finally dissolved in the anhydrous tetrahydrochysenes of 150ml
In furans, 30.3g (0.159mol) Tscl, 24.64g (0.244mol) TEA, 1.5g is then added
(0.122mol) DMAP, is stirred overnight, dichloromethane extraction, anhydrous sodium sulfate drying, filtering,
Recycling design, obtains faint yellow chloro ligustrazine crude product, silica gel post separation [V (petroleum ether):V (acetic acid
Ethyl ester)=10:1] the chloro ligustrazine (compound 5) of water white transparency, yield 80% are obtained.
The standby compound TBA of embodiment 2 preparation
Weigh 12g (26.28mmol) betulic acid, 7.25g (52.56mmol) Anhydrous potassium carbonates in
In 100ml single port bottles, 50mlDMF is added, 5.4g (31.5mmol) chlorine is added after stirring half an hour
For ligustrazine (compound 5), under nitrogen protection, 12h is reacted in 60 DEG C, TLC is detected to anti-
Should be complete, a certain amount of water terminating reaction is added, is then extracted with dichloromethane, collected organic layer,
Appropriate anhydrous sodium sulfate water removal, evaporated under reduced pressure, silica gel post separation [V (petroleum ether):V (acetone)=10:1]
Obtain white solid TBA, fusing point:184.6-185.4 DEG C, yield 90%.1H-NMR(CDCl3)
(ppm):0.78,0.80,0.82,0.96,0.98,1.69(s,each,3H,6×-CH3),2.51(s,3H,
-CH3),2.53(s,3H,-CH3),2.57(s,3H,-CH3),3.02(m,1H),3.19(m,1H),
4.61,4.74 (each, brs, 1H ,=CH2), 5.20,5.23 (each, d, J=12.5Hz, 1H ,-CH2),
1.00–2.50(25H,methyl-and methylene-of triterpenoid structure).13C-NMR
(CDCl3)(ppm):14.7,15.4,15.9,16.1,18.3,19.4,20.9,25.5,27.4,28.0,29.7,
30.6,32.1,34.4,36.9,37.2,38.1,38.7,38.9,40.7,42.4,46.9,49.5,50.6,55.4,
56.7,79.0,109.6,150.5,175.5(-COO-);pyrazine ring:20.4(-CH3),21.4
(-CH3),21.6(-CH3),64.3(-CH2),145.4,148.7,148.9,150.9.HRMS(ESI)
m/z:591.45212[M+H]+, theoretical calculation C38H58N2O3590.44474.
The compound L QC-C of embodiment 3 preparation
Weigh successively 200mg (0.338mmol) TBA, 83.25mg (0.44mmol) Boc-L- methyl amimoacetic acids,
97.20mg (0.50mmol) EDCI and 4.12mg (0.0038mmol) DMAP is placed in 50mL single port bottles
In, adding 5ml anhydrous methylene chloride dissolves it, and TLC [V (dichloromethanes are stirred overnight at room temperature
Alkane):V (methanol)=20:1] reaction process is detected, reaction solution is extracted with dichloromethane, collected organic layer,
Appropriate anhydrous sodium sulfate water removal, evaporated under reduced pressure, silica gel post separation [V (dichloromethane):V (methanol)=40:1]
Obtain white solid;It is dissolved in the ethyl acetate of the HCl containing 3M, ice salt bath stirring 1h;Decompression
Reaction solution is evaporated, appropriate ethyl acetate redissolves, pH is adjusted to neutrality with the sodium bicarbonate solution of saturation,
Collected organic layer, appropriate anhydrous sodium sulfate water removal, evaporated under reduced pressure, silica gel post separation [V (dichloromethanes
Alkane):V (methanol)=40:1] white solid LQC-C, fusing point are obtained:172.6-173.4 DEG C, yield:76.90%.1H-NMR(CDCl3)(ppm):0.77,0.84,0.93(s,each,3H,3×-CH3,methyl of
BA),0.82(brs,6H,2×-CH3,methyl of BA),1.00-2.50(31H,methyl-and
methylene-of BA),2.40,2.50,2.53(s,each,3H,3×-CH3,methyl of TMP),
2.96-3.01(m,1H,-CCHCH2-),3.52(brs,2H,-CH2NH-),4.48-4.51(m,1H,
- OCOCH-), 4.56,4.59 (brs, each, 1H ,=CH2), 5.17,5.20 (d, each, 1H, J=15Hz,
-OCH2-).13C-NMR(CDCl3)(ppm):14.79,16.00,16.28,16.64,18.27,19.47,
20.63,23.85,25.56,28.22,29.75,30.66,32.15,34.35,34.55,37.04,37.21,
38.01,38.18,38.47,40.79,42.53,46.97,49.59,50.58,50.73,55.55,
56.79(-CH-NH2), 83.23 (- OCOCH-), 109.81 (- CH=C-), 151.10 (- CH=C-),
168.63(-COCH-),175.66(-COO-),pyrazine ring:21.02(-CH3),21.51(-CH3),
21.80(-CH3),64.48(-CH2),145.46,148.89,148.98,150.60.HRMS(ESI)m/z:
[M+H]+662.48975, theoretical calculation:C41H63N3O4661.48186.
Embodiment 4
LQC-C 10g are taken, injection (including freeze drying powder injection and aseptic subpackaged dry powder injection) is added
Appropriate auxiliary material, is prepared by injection (including freeze drying powder injection and aseptic subpackaged dry powder injection) technique
Into antineoplastic injection.
Embodiment 5
Take LQC-C 10g, add tablet (including slow-release tablet, matrix tablet, coating tablet, scattered
Piece etc.) appropriate auxiliary material, by tablet (including slow-release tablet, matrix tablet, coating tablet, dispersible tablet etc.)
Technique is prepared into antineoplastic tablet.
Embodiment 6
LQC-C 10g are taken, the appropriate auxiliary material of capsule is added, is prepared into by capsule technique antitumor
Drug Capsule agent.
Embodiment 7
Take LQC-C 10g, emulsion (including micro emulsion, nano-emulsion etc.) appropriate auxiliary material is added, by breast
Agent (including micro emulsion, nano-emulsion etc.) technique is prepared into antincoplastic agents.
Embodiment 8
LQC-C 10g are taken, the appropriate auxiliary material of granule is added, is prepared into by granule technique antitumor
Medicine granule.
Embodiment 9
LQC-C 10g are taken, the appropriate auxiliary material of sustained-release and controlled release agent is added, is made by sustained-release and controlled release agent technique
Antineoplastic sustained-release and controlled release agent.
Embodiment 10
LQC-C 10g are taken, the appropriate auxiliary material of oral liquid is added, is prepared into by oral liquid technique antitumor
Medicine oral liquid.
Embodiment 11
LQC-C 10g are taken, the appropriate auxiliary material of Lipidosome is added, is prepared into by lipid body technology anti-
Tumour medicine Lipidosome.
Claims (10)
1. having the compound or its pharmaceutically acceptable salt of the structure of formula 1, its structural formula is:
2. the compound as claimed in claim 1 or its pharmaceutically acceptable salt, its feature exist
In, add formulation art customary adjuvant be made tablet, capsule, granule, powder, oral liquid,
The regular dosage forms such as injection.
3. the preparation method of compound as claimed in claim 1, it is characterised in that this method includes
Following steps:
Step 1, betulic acid is dissolved in organic solvent, with 2- chloromethyls -3,5,6- trimethyls
Pyrazine generates midbody compound TBA in the basic conditions;
Step 2, midbody compound TBA reacts life in the presence of catalyst with methyl amimoacetic acid
The compound of an accepted way of doing sth 1.
4. preparation method as claimed in claim 3, it is characterised in that react at -20 DEG C extremely
Carried out at 250 DEG C;The organic solvent is the ether containing 1-20 carbon atom, alcohol, alkane, virtue
Fragrant hydrocarbon, ketone, alkyl halide, acid amides, nitrile, the mixture of ester or their various ratios;Alkali used
For triethylamine or potassium carbonate;The catalyst is I-hydroxybenzotriazole, 1- ethyls -3- (3- dimethylamine
Propyl group) carbodiimide hydrochloride, 1,3- dicyclohexylcarbodiimides or DMAP.
5. preparation method as claimed in claim 3, it is characterised in that betulic acid and chloro river
The mol ratio of rhizome of chuanxiong piperazine is 1:0.1~1:10;The mol ratio of betulic acid and alkali is 1:0.1~1:10;TBA
Mol ratio with methyl amimoacetic acid is 1:0.1~1:10;The mol ratio of TBA and catalyst is 1:0.1~1:10.
6. compound as claimed in claim 1 or its pharmaceutically acceptable salt are preparing anticarcinogen
Application in thing.
7. application as claimed in claim 6, it is characterised in that the cancer be liver cancer, lung cancer,
Colon cancer, cervical carcinoma or stomach cancer.
8. pharmaceutical composition, it is characterised in that the composition includes what is existed with therapeutically effective amount
Claim 1 compound or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient
Mixture.
9. composition as claimed in claim 8, it is characterised in that the composition is also comprising extremely
A kind of few conventional anti-cancer drugs.
10. composition as claimed in claim 9, it is characterised in that the anticarcinogen is selected from ring
Phosphamide, 5 FU 5 fluorouracil, taxol, adriamycin, Etoposide, Irinotecan, oxaliplatin,
Cis-platinum or gemzar.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610059173.XA CN107011406A (en) | 2016-01-28 | 2016-01-28 | Compound with anti-tumor effect and preparation method and application thereof |
CN201780003139.3A CN108137644B (en) | 2016-01-28 | 2017-01-16 | Compound with anti-tumor effect and preparation method and application thereof |
PCT/CN2017/071276 WO2017128981A1 (en) | 2016-01-28 | 2017-01-16 | Compound having anti-tumour effect and preparation method and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610059173.XA CN107011406A (en) | 2016-01-28 | 2016-01-28 | Compound with anti-tumor effect and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107011406A true CN107011406A (en) | 2017-08-04 |
Family
ID=59397440
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610059173.XA Pending CN107011406A (en) | 2016-01-28 | 2016-01-28 | Compound with anti-tumor effect and preparation method and application thereof |
CN201780003139.3A Active CN108137644B (en) | 2016-01-28 | 2017-01-16 | Compound with anti-tumor effect and preparation method and application thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780003139.3A Active CN108137644B (en) | 2016-01-28 | 2017-01-16 | Compound with anti-tumor effect and preparation method and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN107011406A (en) |
WO (1) | WO2017128981A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110101872A (en) * | 2019-06-13 | 2019-08-09 | 成都大学 | A kind of reduction-sensitive nano-micelle and preparation method and application |
CN110483419A (en) * | 2019-09-11 | 2019-11-22 | 泰州学院 | A kind of two alkoxide derivative of ligustrazine/azo, preparation method and its usage |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569842B2 (en) * | 2000-08-18 | 2003-05-27 | Board Of Trustees Of The University Of Illinois, The | Method of preparing and use of prodrugs of betulinic acid derivatives |
CN101230082B (en) * | 2006-05-12 | 2010-12-01 | 中国药科大学 | 23-hydroxy betulinic acid derivative, preparation method, preparation and use thereof |
CN101928321B (en) * | 2010-03-02 | 2012-09-05 | 福州大学 | Acidic amino acid chemically-modified ursolic acid derivatives with anti-cancer activities |
CN102675401B (en) * | 2011-03-09 | 2014-08-13 | 雷海民 | Preparation of anti-tumor medicine LQC-Y and application thereof |
CN102344482A (en) * | 2011-07-29 | 2012-02-08 | 温州大学 | Betulinol derivant, preparation method and usage |
CN104548120A (en) * | 2013-10-22 | 2015-04-29 | 北京林业大学 | Polyethylene glycol-betulinic acid conjugate and preparation method thereof |
-
2016
- 2016-01-28 CN CN201610059173.XA patent/CN107011406A/en active Pending
-
2017
- 2017-01-16 WO PCT/CN2017/071276 patent/WO2017128981A1/en active Application Filing
- 2017-01-16 CN CN201780003139.3A patent/CN108137644B/en active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110101872A (en) * | 2019-06-13 | 2019-08-09 | 成都大学 | A kind of reduction-sensitive nano-micelle and preparation method and application |
CN110483419A (en) * | 2019-09-11 | 2019-11-22 | 泰州学院 | A kind of two alkoxide derivative of ligustrazine/azo, preparation method and its usage |
CN110483419B (en) * | 2019-09-11 | 2022-11-29 | 泰州学院 | Ligustrazine/azonium dialkoxide derivative, preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN108137644B (en) | 2020-09-01 |
CN108137644A (en) | 2018-06-08 |
WO2017128981A1 (en) | 2017-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9321804B2 (en) | Synthesis and use of anti-tumor drug LQC-Y | |
CN103044395B (en) | Desloratadine-containing amino acid derivative as well as preparation method and application thereof | |
CN104016956A (en) | 5,2',4'-trihydroxyl-7-methyl-3-hydrocarbyl flavone analogue as well as preparation method and application thereof | |
CN108350023B (en) | Compound with anticancer effect and preparation method and application thereof | |
CN106478760B (en) | Three note analog derivative TBA-X with antitumor action and its preparation method and application | |
CN107011406A (en) | Compound with anti-tumor effect and preparation method and application thereof | |
CN111471080B (en) | ocotillol type ginsengenin A-ring amino thiazole ring derivative and preparation method thereof | |
CN105524076A (en) | Diazeniumdiolate nitric oxide-donating type oridonin derivatives, preparation method and application | |
CN108456239A (en) | Compound BA-X with antitumor action and its preparation method and application | |
CN105859823A (en) | Application of ilicis routundae cortex acid ester derivatives in preparation of anti-tumor drugs | |
CN106317030B (en) | A kind of 4- indyl coumarin derivative and its preparation method and application | |
CN102731454A (en) | Dehydrocostunolide derivative, its pharmaceutical composition, preparation method and application thereof | |
CN106995450B (en) | A kind of triptolide derivative and its preparation method and application | |
CN101974016A (en) | Amide compound and preparation method and applications thereof | |
CN103304573B (en) | Narcissine compounds is preparing the application of antitumor drug | |
CN104003968A (en) | Natural product 3-prenyl Iuteolin analogue (I)/(II), preparation method of natural product 3-prenyl Iuteolin analogue (I)/(II), and application of natural product 3-prenyl Iuteolin analogue (I)/(II) | |
CN106967146A (en) | Oleanolic acid terazole derivatives and its production and use | |
CN104292211A (en) | Desloratadine nitric oxide donor, and preparation method and application thereof | |
CN102786458B (en) | Pyrrole formamide derivative, and preparation method and application thereof | |
CN106317175B (en) | Histone deacetylase inhibitor and preparation method and application thereof | |
CN104672213A (en) | Amide compound with antitumor activity, and application thereof | |
CN103880793B (en) | Containing furan imine compound and its production and use | |
CN104974135B (en) | Targeting DNA has the Sai-Mi-Xi-Bu derivative containing benzene-naphthalene diimide structure of antitumor activity, pharmaceutical composition and its preparation method and application | |
CN102627682A (en) | Esterified and halogenated stigmasterol derivate and application thereof in anti-cancer drugs | |
CN112010791B (en) | Novel lithospermine phenylacetate derivative containing benzenesulfonamide structural unit and synthesis method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170804 |
|
WD01 | Invention patent application deemed withdrawn after publication |